Rubicon Research IPO: The initial public offering (IPO) of Rubicon Research Limited opened today, October 9 and will remain open for public bidding till October 13, 2025. The pharmaceutical formulations company aims to raise around Rs 1377.50 crore from the public offering of 2.84 crore equity shares. The issue was subscribed 51 per cent at the end of the first day of bidding.
The company has reserved approximately 36,082 equity shares (based on the upper cap) for its eligible employees.
From the rest, the Qualified Institutional Buyers (QIBs) quota has been allotted not less than 75 per cent, while not more than 15 per cent is reserved for High-Net-Worth Individuals (HNIs) and not more than 10 per cent for Retail investors.
Add Zee Business as a Preferred Source
Rubicon Research IPO subscription status:
The first day of subscription concluded with investors bidding for 84.57 lakh shares out of the total shares on offer. The subscription includes bids from Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs), subscribing 0.26 times, 0.47 times, and 1.35 times against their allotted portions, respectively.
Rubicon Research IPO details:
The IPO is a maiden book-building issue of Rs 1,377.50 crore, comprising a fresh issue of 1.03 crore equity shares worth Rs 500 crore and an offer for sale (OFS) of 1.80 crore equity shares worth Rs 877.50 crore.
The company plans to utilise the proceeds raised for debt repayment, funding inorganic growth and for general corporate purposes.
Read More: Tata Capital IPO Allotment Today: Here’s how to check status online—Step-by-step process
Price band: Rs 461 to Rs 485 apiece
Face value: Re 1 each
Subscription date: October 9 to October 13, 2025
Lot size: 30 shares
Minimum investment: Rs 14,550 based on the upper end of the price band
Allotment date: October 14, 2025
Listing date: October 16 on BSE and NSE
Rubicon Research company profile:
Rubicon Research Limited is a pharmaceutical formulations company focused on innovation through research and development, with a strong presence in regulated markets, particularly the United States.
They have a portfolio of 66 commercialised products and 72 active ANDAs and NDAs approved by the US FDA.
Financially, the company reported a net profit of Rs. 43.30 crore on a total income of Rs. 356.95 crore in Q1 FY26, which ended on June 30, 2025, from a net profit of Rs. 25.57 crore on a total income of Rs. 321.90 crore for the previous period.
